Inventors:
Peter H. Dobbelaar - Morris Plains NJ, US
Christopher L. Franklin - Keasbey NJ, US
Allan Goodman - Media PA, US
Cheng Guo - Schenectady NY, US
Peter R. Guzzo - Niskayuna NY, US
Mark Hadden - Albany NY, US
Shuwen He - Edison NJ, US
Alan J. Henderson - Albany NY, US
Tianying Jian - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Jian Liu - Edison NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Megan Ruenz - Grayslake IL, US
Bruce J. Sargent - Delmar NY, US
Iyassu K. Sebhat - Jersey City NJ, US
Larry Yet - Albany NY, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
Albany Molecular Research, Inc. - Albany NY
International Classification:
A61K 31/4178
A61K 31/4164
C07D 471/04
C07D 401/10
C07D 403/10
C07D 233/64
US Classification:
514393, 514360, 514385, 514387, 514390, 548126, 5483001, 548416, 548578, 546113, 5462727, 544333, 544405
Abstract:
Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.